Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023
August 03 2023 - 5:00PM
Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic
and synthetic biology solutions, today announced that it will
release its second quarter 2023 financial results on Thursday,
August 10, 2023, after the market closes. In conjunction with the
release, management will host a conference call on Thursday, August
10, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to
discuss the financial results and recent corporate highlights.
The press release and live audio webcast can be accessed via the
Investor section of Telesis Bio’s website at
https://ir.telesisbio.com/. The conference call can be accessed by
registering at this link:
https://register.vevent.com/register/BI5027491b111b49a6a5d05999b6cf5bb6 approximately
5 to 10 minutes before the event to ensure a timely connection.
Upon registration, all telephone participants will receive the
dial-in number along with a unique PIN number that can be used to
access the call. A replay of the conference call webcast will be
available shortly after the live event and archived on
the Investors section of the Telesis Bio website for at
least 30 days.
About Telesis BioTelesis Bio is empowering
scientists with the ability to create novel, synthetic
biology-enabled solutions for many of humanity’s greatest
challenges. As inventors of the industry-standard Gibson Assembly®
method and the first commercial automated benchtop DNA and mRNA
synthesis system, Telesis Bio is enabling rapid, accurate and
reproducible writing of DNA and mRNA for numerous downstream
markets. The award-winning BioXp® system consolidates, automates,
and optimizes the entire synthesis, cloning and amplification
workflow. As a result, it delivers virtually error-free synthesis
of DNA and RNA at scale within days and hours instead of weeks or
months. Scientists around the world are using the technology in
their own laboratories to accelerate the design-build-test paradigm
for novel, high-value products for precision medicine, biologics
drug discovery, vaccine and therapeutic development, genome
editing, and cell and gene therapy. Telesis Bio is a public company
based in San Diego. For more information, visit
www.telesisbio.com.
Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp
are trademarks of Telesis Bio Inc.
Contact:Jen CarrollVice President of Investor
Relationsjen.carroll@telesisbio.com
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Apr 2024 to May 2024
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From May 2023 to May 2024